Hormone Receptor Status in Invasive Breast Cancer

Progesterone Receptor (PR) Testing

Progesterone receptor testing is performed alongside ER testing to provide a more complete picture of the tumor's hormonal sensitivity [[1,2]].

PR Status and Clinical Patterns

A tumor is considered PR+ if 1%–100% of the cells demonstrate nuclear staining [[1,2]]. In clinical practice, most hormone-sensitive tumors follow specific patterns:

1. ER+/PR+: The most common hormone-sensitive profile.
2. ER+/PR-: Still considered hormone-sensitive due to the presence of ER.
3. ER-/PR+: While rare, patients in this subgroup may be considered for endocrine therapy, although clinical data supporting this specific combination are currently limited [[1,2]].

Predicting Efficacy: Expression Levels and Recurrence Scores

Not all HR+ patients will derive the same level of protection from endocrine therapy. The efficacy and the magnitude of risk reduction are influenced by two primary factors [[1,2]]:

1. Level of ER Expression: Generally, higher levels of ER expression correlate with a higher benefit from therapy [[1,2]].
2. Recurrence Score: This is obtained via gene expression assays [[1,2]]. Patients with high recurrence scores may derive relatively less benefit from endocrine therapy alone when compared to those with low recurrence scores [[1,2]].

Endocrine Therapies and Clinical Management

Endocrine therapies are designed to interfere with the estrogen signaling pathway. The choice of therapy often depends on menopausal status and the specific molecular profile of the tumor [[1,2]].

Aromatase Inhibitors (AI) and Bone Health

Aromatase inhibitors are a mainstay of treatment, particularly in postmenopausal women. However, they carry a specific risk regarding Bone Mineral Density (BMD) [[1,2]].

• Risk: Patients receiving AIs are at an increased risk for osteoporosis [[1,2]].
• Monitoring: Baseline assessment and periodic monitoring via dual-energy x-ray absorptiometry (DEXA) scans are recommended [[1,2]].
• Intervention: To maintain BMD and reduce the risk of fractures in postmenopausal patients, the use of bisphosphonates or denosumab is an acceptable clinical intervention [[1,2]].

Tamoxifen and Drug Interactions

Tamoxifen is another common endocrine therapy. When prescribing it, clinicians must be vigilant regarding potential drug-drug interactions, particularly with mental health medications [[1,2]].

Exam Tip: Watch for questions regarding the coadministration of Tamoxifen and certain SSRIs. Certain Selective Serotonin Reuptake Inhibitors (SSRIs), specifically fluoxetine and paroxetine, can interfere with the drug's metabolism [[1,2]].

The mechanism of this interaction involves the inhibition of the enzymes required to convert tamoxifen into its active metabolites, such as endoxifen and 4-OH tamoxifen. This can potentially reduce the overall efficacy of the cancer treatment [[1,2]].